Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

ICON Announces Clinical Research partnership with DuPage Medical Group


Additional PMG Research site locations enhances ICON's site and
patient engagement capabilities

(NASDAQ:ICLR), a global provider of drug development and
commercialisation solutions and services, today announced that PMG
Research, Inc., part of ICON Site and Patient Recruitment, and DuPage
Medical Group of Chicago, Illinois have finalised a Master Agreement
formalising a clinical research partnership. Effective May 2018, PMG
Research will assume the research infrastructure at the DuPage Medical

The expansion of the PMG Research network enhances ICON's ability to
increase access and engagement with investigator sites and patients,
helping customers to reduce the overall time and cost associated with
drug development. The addition of DuPage Medical Group provides
investigator and patient access in the greater Chicago area, while
bringing clinical research as a care option to the communities served.

DuPage Medical Group is the largest independent, multi-specialty
physician group in the Chicagoland area, with practice sites in more
than 100 locations in DuPage, Cook, Grundy, Kane, Kendall and Will
Counties. DuPage Medical Group provides patients with access to more
than 700 physicians in over 50 clinical specialties ranging from primary
care to specialty care in areas such as cardiology and oncology.

"Enrolling and engaging patients in clinical trials continues to be one
of the biggest challenges within drug development. Our partnership with
DuPage Medical Group extends our ability to help customers enhance
clinical trial feasibility and improve patient enrolment timelines
whilst also giving patients access to a broader range of care options
through clinical trials." Commented EB McLindon, Senior Vice President,
Site & Patient Recruitment, ICON. "We are committed to enhancing
engagement with sites, patients and healthcare providers to take
significant time and cost from our customers' development programmes."

Dr. Paul Merrick, President of DuPage Medical Group, agrees, "Through
this collaboration, additional communities in Illinois, along with more
of DuPage Medical Group's patients, will have increased access to
clinical research in a broad range of therapeutic areas. The integration
of clinical research into patient care as a result of partnerships
between healthcare institutions and clinical research site organisations
delivers additional benefits and innovative solutions to the drug
development process; both patients and healthcare providers will
ultimately see lowered costs and faster time to market for potentially
life-saving medications, vaccines, and medical devices."

Dr. Paul Merrick continues, "DuPage Medical Group has participated in
clinical trials and research over the last 13 years in many specialty
areas including dermatology, cardiology, gastroenterology, spine and
otolaryngology. Joining forces with ICON will allow us to continue to
expand access in other areas including oncology and will play an
integral role in advancing the treatment options available to our
patients and the communities we serve."

About ICON plc

ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to pharmaceutical,
biotechnology, medical device, and government and public health
organisations. The company specialises in the strategic development,
management and analysis of programs that support clinical development -
from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 97
locations in 38 countries and has approximately 13,380 employees.
Further information is available at

About PMG Research, Inc.

PMG Research, Inc. part of ICON Site & Patient Recruitment, is an
integrated network of clinical research facilities operating 53 clinics
in 14 cities in North America. It has conducted over 8,100 research
studies for hundreds of pharmaceutical sponsors and CROs since 1979 and
has extensive experience conducting all phases of trials across all
major therapeutic areas with particular experience in cardiology,
dermatology, endocrinology, gastroenterology, men's health, neurology,
pulmonology, rheumatology, vaccine, and women's health trials. Further
information is available at

About DuPage Medical Group

Founded in 1999, DuPage Medical Group is the largest independent,
multi-specialty physician group with more than 700 physicians in over
100 suburban Chicago locations. DMG is a patient-centered organisation
focused on improving access to convenient, quality health care using the
latest technology and treatment options. For more information, visit

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at

View Comments and Join the Discussion!